Study Highlights TargetScan Touch for Improved Prostate Cancer Detection

A recent Duke University study confirms that the TargetScan Touch technology by Envisioneering Medical Technologies offers effective detection and treatment of prostate cancer.

St. Louis, MO, May 03, 2009 --( A study published by Duke University in the April 2009 edition of Technology in Cancer Research and Treatment, confirms that TargetScan® stereotactic prostate biopsy technology prostate cancer detection more frequently than traditional biopsy methods. Recent studies confirm the medical community’s need for more confidence in diagnosing and determining appropriate treatment for prostate cancer.

“Our team feels this platform is a very promising technique, allowing us to repeat biopsies and giving us higher probabilities of locating cancer within the prostate,” explains Thomas J. Polascik, M.D., associate professor of urologic surgery at Duke University Medical Center and co-author of the study.

The Duke Prostate Center study evaluated 68 patients using the TargetScan technology to guide prostate biopsies. From a system generated three-dimensional map of the prostate, the TargetScan algorithm provided a biopsy plan based on measured prostate dimensions.

The system’s fixed template provided physicians with precise position locations from which to draw biopsy samples. The system also maintains the fixed template as a starting point for future prostate biopsies targeting the same region of interest. TargetScan provides a sound basis for active surveillance.

“Our system is based on the physician’s need to locate specific areas within the gland, to repeat biopsies in the future if necessary, confidently design treatment plans, and to provide information that contributes to reducing patient side effects,” says Robert Mills, president, Envisioneering Medical Technologies, the developer of the technology.

About TargetScan and Envisioneering Medical Technologies
TargetScan TouchTM is a stereotactic biopsy and treatment system delivering precision at the touch of the physician’s fingers. The technology collects 3-D images using a proprietary robotic probe; leads physicians in mapping prostate locations; and guides biopsy sampling and/or cancer therapies through needle placement within a defined template. It was developed by Envisioneering Medical Technologies, based in St. Louis, Mo., which develops technology to support the continuum of care for the prostate – from targeted biopsies to guided cancer treatment. For more information please visit

Envisioneering Medical Technologies
Robert Mills